GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CORBUS PHARMACEUTICALS HOLDINGS INC

Financial Performance:

• No specific financial metrics (revenue, earnings, cash flow, debt) were disclosed as the company is a pre-revenue drug development firm.
• Corporate structure identified as a small company with approximately 40 employees based in the Boston area.
• Business model relies on strategic partnerships, specifically noting a collaboration with CSPC for the oncology asset (CRO-02) in China.

Guidance and Future Outlook:

• Oncology (CRO-02): Enrollment for the Phase 3 registrational study (TEMPO-1) in second-line oropharyngeal squamous cell carcinoma has commenced; aiming for accelerated approval filing with interim data expected soon.
• Oncology Frontline: Exploratory data for CRO-02 in combination with Pembrolizumab (first-line) is expected to mature in Q1 next year, targeting ~12-24 patients for response rate readouts.
• Obesity (CRB-913): First scientific presentation of Phase 1b data scheduled for an upcoming conference later this week; exploring combination therapies with oral GLP-1s.
• Long-term Goals: Seeking to establish CRO-02 as a safer ADC alternative to Padcev and position CRB-913 as an oral, non-brain-penetrating weight loss agent with a favorable psychiatric and GI safety profile.

Business Segments and Product Lines:

• Oncology Segment (CRO-02): A Nectin-4 targeting Antibody-Drug Conjugate (ADC) armed with MMAE. Designed to be more stable than Padcev (Enfortumab vedotin) to minimize peripheral neuropathy and skin toxicity.
  • Lead Indication: Second-line treatment for oropharyngeal squamous cell carcinoma (HPV-positive subset).
  • Secondary Indication: Cervical cancer (maturing Phase 1 data due to high Nectin-4 enrichment).
• Obesity Segment (CRB-913): An oral, once-daily inverse agonist of the CB1 GPCR.
  • Mechanism: Engineered for high brain exclusion (1/50th of the brain-to-plasma ratio of first-generation drugs) to avoid psychiatric adverse events.
  • Clinical Results (Phase 1b): 4-month, double-blind, placebo-controlled study in ~250 obese non-diabetic patients. Showed 5% placebo-adjusted weight loss in 3 months (comparable to oral GLP-1 efficacy), with no suicidality and transient, mild depression/anxiety similar to placebo/GLP-1s.

Market and Competitive Landscape:

• Oncology Competition: Differentiates from Padcev via improved safety profile; positioned to fill a gap in second-line therapy where options are scarce (nearly 50% of patients currently receive no treatment).
  • Genmab Update: Acknowledges Genmab's recent frontline data (LAG3-HN1 study) as disruptive for other frontline players but notes minimal impact on CRO-02's second-line positioning, as patients failing frontline therapy still require effective second-line options.
  • EGFR Bispecifics: Noted that many (e.g., Karuna/J&J) exclude HPV-positive oral pharyngeal patients, creating a specific opportunity for CRO-02 in this demographic where EGFR inhibitors show modest efficacy (~13-29% ORR) compared to Padcev's historical 82% in this setting.
• Obesity Competition: Positions CRB-913 as an orthogonal mechanism to GLP-1s (Ozempic, Wegovy, Mounjaro) with similar oral efficacy but potentially better GI tolerability.
  • Novo Nordisk: References their Monlunabamt as a similar brain-excluded strategy; CRB-913 shows comparable weight loss potential with a distinct safety profile.
  • First Generation: Revitalizes a mechanism abandoned 20 years ago (e.g., Rimonabant) by engineering out CNS toxicity.

Risks and Challenges:

• Oncology: Risk that the drug's safety profile, while improved, still precludes frontline use compared to existing standards of care (e.g., Padcev's neuropathy issues in frontline combinations).
• Obesity: Long-term safety and tolerability of the CB1 mechanism remain unproven beyond the 3-4 month study duration; potential risk of cumulative psychiatric events or weight regain post-treatment.
• Development Risks: Dependency on the maturation of exploratory data for the frontline combination study (Q1 next year) to unlock the larger market opportunity; potential regulatory hurdles for a 20-year-old mechanism.

Management Commentary and Tone:

• Tone: Confident, optimistic, and scientifically rigorous. Management emphasizes the "comeback story" of the CB1 mechanism and the strategic engineering of CRO-02 to solve known class toxicity issues.
• Key Messaging: Strong belief that brain exclusion in CB1 agonists enhances peripheral efficacy (contrary to old dogma) and that CRO-02 offers a "frictionless" development path in a neglected second-line market.
• Strategic Clarity: CEO Yuval Cohen clarified they are not building a "Padcev biosimilar" but a superior safety profile version, and explicitly stated they will not compete in the crowded frontline market until data supports it.

Analyst Questions and Answers:

• Question: How does CRO-02 data compare to benchmarks in second-line vs. investigational options?
  • Answer: 43% Objective Response Rate (ORR) in second-line HPV+ oropharyngeal cancer; significantly better than historical standards where nearly 50% of patients receive no treatment due to modest efficacy of existing options.
• Question: What are the implications of Genmab's recent frontline data for CRO-02?
  • Answer: Minimal impact on the second-line opportunity; Genmab's data reinforces the need for effective second-line options after frontline failure. Genmab's exclusion of HPV+ patients is a potential differentiator for CRO-02.
• Question: Why does CRB-913 outperform the old generation of CB1 inverse agonists despite brain exclusion?
  • Answer: Data suggests weight loss is driven by peripheral CB1 action; brain exclusion prevents side effects while flooding the periphery, resulting in higher potency and efficacy than first-gen drugs.
• Question: What are the expectations for long-term psychiatric safety of CRB-913?
  • Answer: Safety signals (anxiety, irritability) mirror GLP-1s—occurring early and transiently with a natural adaptation process; no evidence of worsening or cumulative effects over time in the study duration.

Other Key Points:

• Partnership Structure: Both assets involve international collaboration (CSPC for oncology); the obesity drug is a wholly-owned asset with a mechanism similar to a Novartis attempt.
• Patient Demographics: Specific focus on HPV-positive patients in head and neck cancer, a subgroup often excluded by other current therapies.
• Combination Potential: Preclinical data suggests CRB-913 could be combined with oral GLP-1s to enhance efficacy without worsening GI side effects.
• Data Readiness: The company is preparing a full scientific presentation for the obesity data later in the week to address the specific historical skepticism surrounding the CB1 mechanism.